Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of YL201 in metastatic castration-resistant prostate cancer
CTR20240246Phase 2Active
- Sponsor
- MediLink Therapeutics
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL201 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by MediLink Therapeutics. Started Mar 2024; status: active.
02
Drugs
YL201
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20240246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240246.